BACKGROUND: According to genome wide association studies, SLC30A8 is among the loci containing SNPs associated with type 2 diabetes (T2D) risk. This gene encodes an islet zinc transporter (ZnT8). OBJECTIVE: To provide new information on the association of the SNP rs11558471 in SLC30A8 gene with IL-17 levels and insulin resistance in an Iranian population with T2D. METHODS: A total of 133 patients with T2D and 128 control subjects were included in this study. Insulin and IL-17 concentrations were determined using ELISA. Insulin and fasting blood glucose levels were employed to determine homeostasis model assessment for insulin resistance (HOMA-IR). PCR-based restriction fragment length polymorphism was performed to determine rs11558471 polymorphism. RESULTS: The risk allele frequency of rs11558471 in studied population was among the highest frequencies in different populations. In T2D patients, compared with the GG genotypes, IL-17 concentrations were significantly higher in the GA+AA group (p=0.042). According to the genotypes of this SNP, IL-17 concentrations, fasting blood glucose and HOMA-IR increased with the following order: GG<GA<AA. A multiple regression revealed that following an adjustment for age and gender, rs11558471 as an independent variable was significantly associated with IL-17 (p=0.039), fasting blood glucose (p=0.003) and HOMA-IR (p=0.042) as the dependent variables. CONCLUSION: The present study demonstrated for the first time, the genetic association of rs11558471 with IL-17 and glycemic traits in Iranian patients with T2D. The association of rs11558471 with glycemic traits showed that it might be useful for the identification of individuals who are at high risk for the development of T2D.
BACKGROUND: According to genome wide association studies, SLC30A8 is among the loci containing SNPs associated with type 2 diabetes (T2D) risk. This gene encodes an islet zinc transporter (ZnT8). OBJECTIVE: To provide new information on the association of the SNP rs11558471 in SLC30A8 gene with IL-17 levels and insulin resistance in an Iranian population with T2D. METHODS: A total of 133 patients with T2D and 128 control subjects were included in this study. Insulin and IL-17 concentrations were determined using ELISA. Insulin and fasting blood glucose levels were employed to determine homeostasis model assessment for insulin resistance (HOMA-IR). PCR-based restriction fragment length polymorphism was performed to determine rs11558471 polymorphism. RESULTS: The risk allele frequency of rs11558471 in studied population was among the highest frequencies in different populations. In T2D patients, compared with the GG genotypes, IL-17 concentrations were significantly higher in the GA+AA group (p=0.042). According to the genotypes of this SNP, IL-17 concentrations, fasting blood glucose and HOMA-IR increased with the following order: GG<GA<AA. A multiple regression revealed that following an adjustment for age and gender, rs11558471 as an independent variable was significantly associated with IL-17 (p=0.039), fasting blood glucose (p=0.003) and HOMA-IR (p=0.042) as the dependent variables. CONCLUSION: The present study demonstrated for the first time, the genetic association of rs11558471 with IL-17 and glycemic traits in Iranian patients with T2D. The association of rs11558471 with glycemic traits showed that it might be useful for the identification of individuals who are at high risk for the development of T2D.